Use of hemi-equilibrium to determine the dissociation kinetics of histamine H3 receptor antagonists.

Sanja Bosnyak; Darren Riddy; Anna Evelyn Cook; Natalie Diepenhorst; Patrick Michael Sexton; Arthur Christopoulos; Christopher Langmead

Use of hemi-equilibrium to determine the dissociation kinetics of histamine H3 receptor antagonists.

Sanja Bosnyak, Darren Riddy, Anna Evelyn Cook, Natalie Diepenhorst, Patrick Michael Sexton, Arthur Christopoulos, Christopher Langmead

Drug Discovery Biology

Research output: Contribution to conference › Poster › peer-review

Abstract

Antagonism of the histamine H3 receptor has been shown to be a potential benefit for patients of obesity, allergic rhinitis and cognitive disorders, including schizophrenia and Alzheimer’s. There are two major isoforms of the histamine H3 receptor, hH3-445 and hH3-365, which have been shown to display differential pharmacology. However, no investigation into the kinetic parameters of histamine H3 antagonists, at either isoform, has been performed.

Original language	English
Number of pages	1
Publication status	Published - 2014
Event	ASCEPT-MPGPCR 2014 - Melbourne Convention and Exhibition Centre, Melbourne, Australia Duration: 7 Dec 2014 → 11 Dec 2014 https://www.asceptasm.com/2014-annual-scientific-meeting/program-keynote-speakers/

Conference

Conference	ASCEPT-MPGPCR 2014
Abbreviated title	ASCEPT-MPGPCR
Country/Territory	Australia
City	Melbourne
Period	7/12/14 → 11/12/14
Internet address	https://www.asceptasm.com/2014-annual-scientific-meeting/program-keynote-speakers/

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@conference{70c5c7522ab147738a3e001467dd9394,

title = "Use of hemi-equilibrium to determine the dissociation kinetics of histamine H3 receptor antagonists.",

abstract = "Antagonism of the histamine H3 receptor has been shown to be a potential benefit for patients of obesity, allergic rhinitis and cognitive disorders, including schizophrenia and Alzheimer{\textquoteright}s. There are two major isoforms of the histamine H3 receptor, hH3-445 and hH3-365, which have been shown to display differential pharmacology. However, no investigation into the kinetic parameters of histamine H3 antagonists, at either isoform, has been performed.",

author = "Sanja Bosnyak and Darren Riddy and Cook, {Anna Evelyn} and Natalie Diepenhorst and Sexton, {Patrick Michael} and Arthur Christopoulos and Christopher Langmead",

year = "2014",

language = "English",

note = "ASCEPT-MPGPCR 2014, ASCEPT-MPGPCR ; Conference date: 07-12-2014 Through 11-12-2014",

url = "https://www.asceptasm.com/2014-annual-scientific-meeting/program-keynote-speakers/",

}

TY - CONF

T1 - Use of hemi-equilibrium to determine the dissociation kinetics of histamine H3 receptor antagonists.

AU - Bosnyak, Sanja

AU - Riddy, Darren

AU - Cook, Anna Evelyn

AU - Diepenhorst, Natalie

AU - Sexton, Patrick Michael

AU - Christopoulos, Arthur

AU - Langmead, Christopher

PY - 2014

Y1 - 2014

N2 - Antagonism of the histamine H3 receptor has been shown to be a potential benefit for patients of obesity, allergic rhinitis and cognitive disorders, including schizophrenia and Alzheimer’s. There are two major isoforms of the histamine H3 receptor, hH3-445 and hH3-365, which have been shown to display differential pharmacology. However, no investigation into the kinetic parameters of histamine H3 antagonists, at either isoform, has been performed.

AB - Antagonism of the histamine H3 receptor has been shown to be a potential benefit for patients of obesity, allergic rhinitis and cognitive disorders, including schizophrenia and Alzheimer’s. There are two major isoforms of the histamine H3 receptor, hH3-445 and hH3-365, which have been shown to display differential pharmacology. However, no investigation into the kinetic parameters of histamine H3 antagonists, at either isoform, has been performed.

M3 - Poster

T2 - ASCEPT-MPGPCR 2014

Y2 - 7 December 2014 through 11 December 2014

ER -